Linked Life Data

17138817

Source:http://linkedlifedata.com/resource/pubmed/id/17138817

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:17138817rdf:typepubmed:Citationlld:pubmed
pubmed-article:17138817lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:17138817lifeskim:mentionsumls-concept:C0023473lld:lifeskim
pubmed-article:17138817lifeskim:mentionsumls-concept:C0010802lld:lifeskim
pubmed-article:17138817lifeskim:mentionsumls-concept:C1704632lld:lifeskim
pubmed-article:17138817lifeskim:mentionsumls-concept:C0871261lld:lifeskim
pubmed-article:17138817lifeskim:mentionsumls-concept:C0231174lld:lifeskim
pubmed-article:17138817lifeskim:mentionsumls-concept:C1455147lld:lifeskim
pubmed-article:17138817lifeskim:mentionsumls-concept:C0935989lld:lifeskim
pubmed-article:17138817lifeskim:mentionsumls-concept:C2911692lld:lifeskim
pubmed-article:17138817lifeskim:mentionsumls-concept:C1706817lld:lifeskim
pubmed-article:17138817lifeskim:mentionsumls-concept:C0205263lld:lifeskim
pubmed-article:17138817lifeskim:mentionsumls-concept:C0205488lld:lifeskim
pubmed-article:17138817pubmed:issue6lld:pubmed
pubmed-article:17138817pubmed:dateCreated2007-3-7lld:pubmed
pubmed-article:17138817pubmed:abstractTextAlthough imatinib induces marked responses in patients with chronic myeloid leukemia (CML), resistance is increasingly problematic, and treatment options for imatinib-resistant or -intolerant CML are limited. Dasatinib, a novel, highly potent, oral, multitargeted kinase inhibitor of BCR-ABL and SRC family kinases, induced cytogenetic responses in a phase 1 study in imatinib-resistant or -intolerant CML and was well tolerated. Initial results are presented from a phase 2 study of 186 patients with imatinib-resistant or -intolerant chronic-phase CML (CML-CP) designed to further establish the efficacy and safety of dasatinib (70 mg twice daily). At 8-months' follow-up, dasatinib induced notable responses, with 90% and 52% of patients achieving complete hematologic and major cytogenetic responses (MCyR), respectively. Responses were long lasting: only 2% of patients achieving MCyR progressed or died. Importantly, comparable responses were achieved by patients carrying BCR-ABL mutations conferring imatinib resistance. Dasatinib also induced molecular responses, reducing BCR-ABL/ABL transcript ratios from 66% at baseline to 2.6% at 9 months. Nonhematologic adverse events were generally mild to moderate, and most cytopenias were effectively managed with dose modifications. Cross-intolerance with imatinib was not evident. To conclude, dasatinib induces notable responses in imatinib-resistant or -intolerant CML-CP, is well tolerated, and represents a promising therapeutic option for these patients. This trial was registered at www.clinicaltrials.gov as CA180013.lld:pubmed
pubmed-article:17138817pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17138817pubmed:languageenglld:pubmed
pubmed-article:17138817pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17138817pubmed:citationSubsetAIMlld:pubmed
pubmed-article:17138817pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17138817pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17138817pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17138817pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17138817pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17138817pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17138817pubmed:statusMEDLINElld:pubmed
pubmed-article:17138817pubmed:monthMarlld:pubmed
pubmed-article:17138817pubmed:issn0006-4971lld:pubmed
pubmed-article:17138817pubmed:authorpubmed-author:DrukerBrian...lld:pubmed
pubmed-article:17138817pubmed:authorpubmed-author:BaccaraniMich...lld:pubmed
pubmed-article:17138817pubmed:authorpubmed-author:CervantesFran...lld:pubmed
pubmed-article:17138817pubmed:authorpubmed-author:StoneRichard...lld:pubmed
pubmed-article:17138817pubmed:authorpubmed-author:FaconThierryTlld:pubmed
pubmed-article:17138817pubmed:authorpubmed-author:KantarjianHag...lld:pubmed
pubmed-article:17138817pubmed:authorpubmed-author:NiederwieserD...lld:pubmed
pubmed-article:17138817pubmed:authorpubmed-author:ApperleyJane...lld:pubmed
pubmed-article:17138817pubmed:authorpubmed-author:GoldbergStuar...lld:pubmed
pubmed-article:17138817pubmed:authorpubmed-author:HochhausAndre...lld:pubmed
pubmed-article:17138817pubmed:authorpubmed-author:SilverRichard...lld:pubmed
pubmed-article:17138817pubmed:authorpubmed-author:HughesTimothy...lld:pubmed
pubmed-article:17138817pubmed:authorpubmed-author:ShahNeil PNPlld:pubmed
pubmed-article:17138817pubmed:authorpubmed-author:LiptonJeffrey...lld:pubmed
pubmed-article:17138817pubmed:authorpubmed-author:EzzeddineRana...lld:pubmed
pubmed-article:17138817pubmed:authorpubmed-author:MullerMartin...lld:pubmed
pubmed-article:17138817pubmed:authorpubmed-author:Countouriotis...lld:pubmed
pubmed-article:17138817pubmed:issnTypePrintlld:pubmed
pubmed-article:17138817pubmed:day15lld:pubmed
pubmed-article:17138817pubmed:volume109lld:pubmed
pubmed-article:17138817pubmed:ownerNLMlld:pubmed
pubmed-article:17138817pubmed:authorsCompleteYlld:pubmed
pubmed-article:17138817pubmed:pagination2303-9lld:pubmed
pubmed-article:17138817pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:17138817pubmed:meshHeadingpubmed-meshheading:17138817...lld:pubmed
pubmed-article:17138817pubmed:meshHeadingpubmed-meshheading:17138817...lld:pubmed
pubmed-article:17138817pubmed:meshHeadingpubmed-meshheading:17138817...lld:pubmed
pubmed-article:17138817pubmed:meshHeadingpubmed-meshheading:17138817...lld:pubmed
pubmed-article:17138817pubmed:meshHeadingpubmed-meshheading:17138817...lld:pubmed
pubmed-article:17138817pubmed:meshHeadingpubmed-meshheading:17138817...lld:pubmed
pubmed-article:17138817pubmed:meshHeadingpubmed-meshheading:17138817...lld:pubmed
pubmed-article:17138817pubmed:meshHeadingpubmed-meshheading:17138817...lld:pubmed
pubmed-article:17138817pubmed:meshHeadingpubmed-meshheading:17138817...lld:pubmed
pubmed-article:17138817pubmed:meshHeadingpubmed-meshheading:17138817...lld:pubmed
pubmed-article:17138817pubmed:meshHeadingpubmed-meshheading:17138817...lld:pubmed
pubmed-article:17138817pubmed:meshHeadingpubmed-meshheading:17138817...lld:pubmed
pubmed-article:17138817pubmed:meshHeadingpubmed-meshheading:17138817...lld:pubmed
pubmed-article:17138817pubmed:meshHeadingpubmed-meshheading:17138817...lld:pubmed
pubmed-article:17138817pubmed:meshHeadingpubmed-meshheading:17138817...lld:pubmed
pubmed-article:17138817pubmed:meshHeadingpubmed-meshheading:17138817...lld:pubmed
pubmed-article:17138817pubmed:meshHeadingpubmed-meshheading:17138817...lld:pubmed
pubmed-article:17138817pubmed:year2007lld:pubmed
pubmed-article:17138817pubmed:articleTitleDasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy.lld:pubmed
pubmed-article:17138817pubmed:affiliationIII. Medizinische Klinik, Medizinische Fakultät Mannheim, Universität Heidelberg, Theodor-Kutzer-Ufer 1-3, 68167 Mannheim, Germany. hochhaus@uni-hd.delld:pubmed
pubmed-article:17138817pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:17138817pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
pubmed-article:17138817pubmed:publicationTypeClinical Trial, Phase IIlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17138817lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17138817lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17138817lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17138817lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17138817lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17138817lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17138817lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17138817lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17138817lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17138817lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17138817lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17138817lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17138817lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17138817lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17138817lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17138817lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17138817lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17138817lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17138817lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17138817lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17138817lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17138817lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17138817lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17138817lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17138817lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17138817lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17138817lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17138817lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17138817lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17138817lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17138817lld:pubmed
More...